Key Insights

Highlights

Success Rate

88% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

4.0%

2 terminated out of 50 trials

Success Rate

87.5%

+1.0% vs benchmark

Late-Stage Pipeline

18%

9 trials in Phase 3/4

Results Transparency

7%

1 of 14 completed with results

Key Signals

1 with results88% success

Data Visualizations

Phase Distribution

30Total
Not Applicable (9)
P 1 (4)
P 2 (8)
P 3 (3)
P 4 (6)

Trial Status

Recruiting15
Completed14
Unknown13
Not Yet Recruiting3
Enrolling By Invitation2
Terminated2

Trial Success Rate

87.5%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (50)

Showing 20 of 20 trials
NCT02682511Phase 2Active Not Recruiting

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

NCT03626688Phase 3Completed

A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

NCT07283081Not ApplicableRecruiting

Impact of Capillaroscopy in the Investigation of Diffuse Interstitial Pneumonias

NCT06104228Phase 2Recruiting

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

NCT03683186Phase 3Enrolling By Invitation

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

NCT07329556Not Yet Recruiting

Skin Autofluorescence Assessment of Advanced Glycation End Products in Rheumatic Diseases

NCT06455384Not ApplicableRecruiting

The Genetics Navigator: Evaluating a Digital Platform for Genomics Health Services

NCT06716606Phase 3RecruitingPrimary

A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

NCT05516758Phase 2Terminated

A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid Arthritis

NCT00802607Terminated

Collection of Tissue Specimens for Analysis and Establishment of Cell Cultures

NCT04664478Completed

Gene First Approach to Connective Tissue Disease

NCT07152223Not ApplicableRecruitingPrimary

Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases

NCT07117552Not Yet RecruitingPrimary

Study for Patients With Connective Tissue Diseases Who Suffer From Pleuropulmonary Symptoms Clinically and Radiologically

NCT05998759Phase 2RecruitingPrimary

Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

NCT02392130Phase 1Completed

A Clinical Trial to Assess the Potential of LEO 130852A Gel to Reduce Steroid Induced Skin Atrophy on Healthy Skin

NCT04993885Phase 2Recruiting

Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

NCT06732674Not ApplicableRecruiting

Home Based Clinical Management of Interstitial Lung Disease in Systemic Rheumatic Diseases

NCT06702228RecruitingPrimary

Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland

NCT06574581Phase 1RecruitingPrimary

ADSCs Therapy in Patients With CTD-ILD

NCT04915482Phase 2Recruiting

TPO-RAs Combined With Anti-CD20 Antibody in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Scroll to load more

Research Network

Activity Timeline